Mirum Pharmaceuticals, Inc. filings document operating results, product-sales disclosures, clinical program updates and governance matters for a rare disease biopharmaceutical company. Its 8-K reports furnish earnings releases, preliminary sales information, Regulation FD investor materials and other event disclosures tied to LIVMARLI, CHOLBAM, CTEXLI and investigational programs such as volixibat and brelovitug.
The company’s SEC record also covers capital-structure and transaction disclosures, including the completed Bluejay Therapeutics acquisition, related pro forma financial information and a PIPE financing. Proxy filings describe annual meeting matters, board elections, executive compensation and equity-plan governance, while registration details identify Mirum common stock as listed on the Nasdaq Global Market under MIRM.
Mirum Pharmaceuticals insider Peter Radovich has filed a Form 144 to sell 3,143 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 304,619.56, out of 51,393,574 shares outstanding.
The shares were acquired on 01/23/2026 as restricted stock units vesting under a registered plan, as compensation for services to the issuer. The filing also notes that during the past three months Radovich sold 2,382 shares of common stock on 01/22/2026 for gross proceeds of 222,300.69.
Mirum Pharmaceuticals stockholder plans to sell recently vested shares. A person named Christopher Peetz filed a notice to sell 6,831 shares of Mirum Pharmaceuticals common stock through Morgan Stanley Smith Barney LLC on or about 01/26/2026 on NASDAQ, with an aggregate market value of 662,060.52.
These shares were acquired on 01/23/2026 as restricted stock units vesting under a registered plan, as compensation for services rendered to the issuer. The notice also reports that during the past three months, the same seller disposed of 7,098 shares of common stock for gross proceeds of 662,422.46.
Mirum Pharmaceuticals’ chief financial officer Eric Bjerkholt reported routine equity compensation activity. On January 23, 2026, 2,667 restricted stock units vested and converted into the same number of common shares at an exercise price of $0. On January 26, 2026, he sold 1,053 of these shares at $96.192 per share to cover tax withholding obligations linked to the vesting. After these transactions, he directly owns 43,741 shares of common stock and 2,666 restricted stock units, which continue to vest in equal annual installments through the three-year schedule that began January 23, 2024.
Mirum Pharmaceuticals’ president and COO Peter Radovich reported routine equity transactions. On January 23, 2026, 5,750 restricted stock units vested and were converted to 5,750 shares of common stock at an exercise price of $0, increasing his directly held common shares to 26,429.
On January 26, 2026, he sold 3,143 shares of common stock at $96.192 per share, mainly to cover tax withholding on the vesting. After these transactions, he directly owned 23,286 shares of Mirum common stock and 5,750 restricted stock units, which continue to vest in thirds on each anniversary of January 23, 2024.
Mirum Pharmaceuticals SVP and Global Controller Jolanda Howe reported routine equity transactions. On January 23, 2026, 1,500 restricted stock units vested and converted into 1,500 shares of common stock at an exercise price of $0, increasing her directly held common stock to 4,542 shares.
On January 26, 2026, Howe sold 842 shares of Mirum common stock at $96.192 per share to cover tax withholding obligations tied to the RSU vesting. After these transactions, she directly owned 3,700 shares of common stock and 1,500 restricted stock units, which continue to vest in thirds annually from January 23, 2024.
Mirum Pharmaceuticals chief executive Christopher Peetz reported routine equity activity involving company stock. On January 23, 2026, he exercised 12,500 restricted stock units, each converting into one share of common stock at an exercise price of $0, increasing his direct holdings to 176,233 shares.
On January 26, 2026, Peetz sold 6,831 shares of common stock at $96.192 per share, with the filing stating these shares were sold to cover tax withholding tied to the RSU vesting. After the sale, he directly owned 169,402 shares and also beneficially owned 187,500 shares indirectly through The Peetz Family Trust.
Mirum Pharmaceuticals director Patrick J. Heron reported indirect fund activity in Mirum stock. On January 23, 2026, Frazier Life Sciences X, L.P., an investment fund associated with him, received 159,277 shares of Mirum common stock in connection with the merger of Bluejay Therapeutics into Mirum, when Mirum’s closing share price was $94.29. That same day, Frazier Life Sciences X, L.P. also purchased 131,425 shares of Mirum common stock at $68.48 per share.
After these transactions, Frazier Life Sciences X, L.P. held 459,010 Mirum shares indirectly reported by Heron, and Frazier Life Sciences IX, L.P. held 3,566,912 shares. Heron also reported 5,703 Mirum shares held directly in his own name. The footnotes state that the Frazier funds hold the shares directly and that Heron disclaims beneficial ownership of those fund-held securities except to the extent of his pecuniary interest.
Frazier Life Sciences-affiliated funds and managers have updated their ownership disclosures in Mirum Pharmaceuticals, Inc. (MIRM) through Amendment No. 8 to a Schedule 13D. The filing shows Frazier Life Sciences IX, L.P. holding 3,566,912 shares of common stock, representing 5.9% of the class, and Frazier Life Sciences X, L.P. holding 459,010 shares, or 0.8%. Frazier Life Sciences Public Fund, L.P. holds 2,514,947 shares, or 4.2%, while other Frazier funds hold smaller stakes.
The filing attributes 4,025,922 shares, or 6.7% of the class, to James N. Topper through shared voting and investment power over certain funds, and 4,108,404 shares, or 6.8%, to Patrick J. Heron, including 76,779 option shares. The investors state the shares were acquired for investment purposes and that they have no present plans for mergers, control changes, or other major corporate actions. A registration rights agreement dated December 7, 2025 entitles several Frazier funds to have Mirum register for resale both their common shares and shares underlying pre-funded warrants purchased on January 23, 2026, including warrants held by the public fund subject to a 9.99% beneficial ownership cap.
Mirum Pharmaceuticals has completed its acquisition of Bluejay Therapeutics, using a mix of cash, stock and potential future milestone payments. At closing, Mirum acquired Bluejay’s net cash of approximately $56.6 million and agreed to pay Target security holders up to $280.8 million in cash and 4,673,597 shares of Mirum common stock as upfront consideration, plus up to $25.8 million in cash and 522,375 shares as holdback consideration. The deal also includes up to $200 million in cash milestone payments tied to net sales. Following the mergers and related private placements, 59,879,958 shares of Mirum common stock were issued and outstanding as of January 23, 2026. Certain funds affiliated with Frazier Life Sciences, linked to a Mirum director and owning more than five percent of Mirum’s stock, participated as Bluejay security holders and will receive their pro rata share of the merger consideration.
Mirum Pharmaceuticals senior vice president and global controller Jolanda Howe reported equity transactions tied to the vesting of restricted stock units. On January 21, 2026, 1,542 restricted stock units were converted into the same number of common shares at an exercise price of $0, reflecting the scheduled vesting of her award. On January 22, 2026, 926 common shares were sold at an average price of $93.3252 to cover tax withholding obligations related to this vesting. After these transactions, Howe directly held 3,042 shares of common stock and 3,083 restricted stock units, which continue to vest in equal annual installments through the third anniversary of January 21, 2025.